ЧÀÍÈÈÏß
×ðÖØ¿Æѧ ¾´Î·ÖÆ¶È ×·ÇóЧÂÊ ¹Ø°®ÉúÃü
ѧÊõ¶¯Ì¬
ÀûÀ´w66¹¹½¨LOXO-292ÄÍÒ©Ë«Í»±ä¹¤³Ìϸ°ûÖêÖúÁ¦RETÒÖÖƼÁ¿ª·¢
Ðû²¼Ê±¼ä£º
2021-06-22
RET£¨Rearranged during transfection£©»ùÒòÓÚ1985ÄêÊ×´ÎÔÚÈËTÁÜ°ÍÁöϸ°ûÖз¢Ã÷£¬£¬£¬£¬£¬ £¬ÇÒ±»ÅжÏΪһ¸öÔ°©»ùÒò£¬£¬£¬£¬£¬ £¬RET»ùÒòλÓÚÈËÀà10ºÅ³£È¾É«Ì峤±Û£¨10q11.2£©£¬£¬£¬£¬£¬ £¬±àÂëÒ»ÖÖ±£´æÓÚϸ°ûĤÉϵÄÊÜÌåÀÒ°±Ëἤø£¨RTK£©[1]¡£ ¡£¡£¡£¡£ ¡£¡£¡£RETÂÑ°×ÔÚ³ÉÊìÀú³ÌÖУ¬£¬£¬£¬£¬ £¬ÂÑ°×Ç°Ìåͨ¹ý²î±ðµÄÑ¡ÔñÐÔ¼ôÇз½·¨£¬£¬£¬£¬£¬ £¬Ö÷ÒªÐγÉÁ½ÖÖÂÑ°×ÑÇÐÍRET-9ºÍRET-51¡£ ¡£¡£¡£¡£ ¡£¡£¡£RET¼¤Ã¸±»Éñ¾½ºÖÊϸ°ûϵȪԴµÄÉñı»®ÑøÉú³¤Òò×ÓGDNF¼¤»î£¬£¬£¬£¬£¬ £¬GFNFÓëGFRα1Á¬ÏµÐγÉGDNF-GFRα1¸´ºÏÎ£¬£¬£¬£¬ £¬´Ë¸´ºÏÎïÔÙÓëRETÁ¬ÏµÐγÉÈý¸´ºÏÌ壬£¬£¬£¬£¬ £¬ÒýÆðRETµÄ¶þ¾Û»¯£¬£¬£¬£¬£¬ £¬²¢ÒýÆðÀÒ°±Ëá²Ð»ù×ÔÁ×Ëữ£¬£¬£¬£¬£¬ £¬´Ó¶ø¼¤»îÏÂÓÎÐźÅͨ·[2]£¬£¬£¬£¬£¬ £¬°üÀ¨RAS/MARK¡¢PI3K/AKT¡¢PLCγ/PKCµÈÐźÅͨ·£¬£¬£¬£¬£¬ £¬½ø¶øÒýÆðϸ°ûµÄÔöÖ³·Ö½â¡¢Ç¨áã¡¢ÔÙÉúºÍÉú³¤µÈ[1]¡£ ¡£¡£¡£¡£ ¡£¡£¡£
ͼ1. a) RET¼¤Ã¸½á¹¹;b) RET¼¤Ã¸»î»¯»úÖƼ°ÐźÅͨ·¡£ ¡£¡£¡£¡£ ¡£¡£¡£
(ͼƬȪԴÓڲο¼×ÊÁÏ[2])
RET»ùÒòÖ°©»úÖÆ£¬£¬£¬£¬£¬ £¬Ö÷ÒªÓлùÒòÈںϡ¢µãÍ»±ä¡¢»ùÒòÀ©ÔöºÍȾɫÌåÖØÅŵÈ[3]¡£ ¡£¡£¡£¡£ ¡£¡£¡£È¾É«ÌåµÄÖØ×é³£»£»£»£»£»£»áµ¼ÖÂRET»ùÒòÖÐÖÐÖ¹ÁѺóÓë²î±ðµÄÉÏÓλùÒò±¬·¢Èںϣ¬£¬£¬£¬£¬ £¬½ø¶øÐγÉÇý¶¯Ö×Áöϸ°ûÔöÖ³µÄÈںϻùÒò¡£ ¡£¡£¡£¡£ ¡£¡£¡£ÔÚ1990ÄêºÍ2012ÄêÏȺóÔÚ¼××´ÏÙÈéÍ·×´°©¡¢·ÎÏÙ°©ºÍÂýÐÔËèϵ°×Ѫ²¡Öз¢Ã÷ÕâÒ»±äÒì¡£ ¡£¡£¡£¡£ ¡£¡£¡£ÆäÖÐÈںϻùÒòÖ÷ÒªÓУºKIF5B-RET£¨×î¶à£©£¬£¬£¬£¬£¬ £¬CCDC6-RETºÍNCOA4-RET£»£»£»£»£»£»RET»ùÒòÔÚNSCLC»¼ÕßÖ÷ÒªÒÔRET»ùÒòÈÚºÏÐÎʽ±¬·¢¸Ä±ä£¬£¬£¬£¬£¬ £¬Ñо¿ÏÔʾ·ÇСϸ°û·Î°©ÖÐKIF5B©\RETÈÚºÏÔ¼Õ¼ËùÓÐRETÈÚºÏµÄ 68.3 %£¬£¬£¬£¬£¬ £¬Æä´ÎΪCCDC6©\RET (16.8 %)¼°NCOA4©\RET (1.2 %)[4]¡£ ¡£¡£¡£¡£ ¡£¡£¡£ËäÈ»RET»ùÒòÔÚNSCLC»¼ÕßÖеķ¢²¡ÂʽöΪ1.4 %-2.5 %£¬£¬£¬£¬£¬ £¬¿ÉÊÇÎÒ¹úµÄ»¼Õß»ùÊýºÜÊǴ󣬣¬£¬£¬£¬ £¬Òò¶øЯ´øRET»ùÒòÈںϵÄNSCLC»¼Õß²¢²»ÉÙ¼û[5]¡£ ¡£¡£¡£¡£ ¡£¡£¡£µãÍ»±ä¶àλÓÚGate keeper²Ð»ù£¬£¬£¬£¬£¬ £¬Ö÷ÒªÊÇV804λµã£¨V804M£¬£¬£¬£¬£¬ £¬V804L£©£¬£¬£¬£¬£¬ £¬»¹°üÀ¨ÈܼÁÇ°ÑØÍ»±äG810λµã£¨G810R£¬£¬£¬£¬£¬ £¬G810S£¬£¬£¬£¬£¬ £¬G810C£¬£¬£¬£¬£¬ £¬G810A£¬£¬£¬£¬£¬ £¬G810V£©¡¢M918TºÍC634λµã£¨C634R£¬£¬£¬£¬£¬ £¬C634G£¬£¬£¬£¬£¬ £¬C634F£¬£¬£¬£¬£¬ £¬C634S£¬£¬£¬£¬£¬ £¬C634W£¬£¬£¬£¬£¬ £¬C634Y£¬£¬£¬£¬£¬ £¬C634K£©Í»±äµÈ[1]¡£ ¡£¡£¡£¡£ ¡£¡£¡£
ͼ2. ²î±ð°©Ö¢ÖÐRET»ùÒò¸Ä±äµÄ¸ÅÊö¡£ ¡£¡£¡£¡£ ¡£¡£¡£
(ͼƬȪԴÓڲο¼×ÊÁÏ[3])
ͼ3. RET»ùÒòµÄÖ÷ÒªÈںϷ½·¨ºÍµãÍ»±äλµã¡£ ¡£¡£¡£¡£ ¡£¡£¡£
(ͼƬȪԴÓڲο¼×ÊÁÏ[1])
2011ÄêºÍ2013Ä꣬£¬£¬£¬£¬ £¬FDAºÍEMA»®·ÖÅú×¼VandetanibºÍCabozantinibÓÃÓÚÖÎÁÆÏ£ÍûµÄÍíÆÚµÄMTC»¼Õߣ¬£¬£¬£¬£¬ £¬²¢ÒÑÔÚRETÈÚºÏÑôÐÔNSCLC»¼ÕßÖÐÏÔʾ³ö»îÐÔ[1]¡£ ¡£¡£¡£¡£ ¡£¡£¡£µ«ÉÏÊöÒ©ÎïÕûÌå¹ØÓÚRET»ùÒòÈÚºÏÍ»±äµÄ°ÐÏòÌØÒìÐÔ²¢²»Ç¿£¬£¬£¬£¬£¬ £¬Æä²»µ«ÒÖÖÆRETÂÑ°×Ðźţ¬£¬£¬£¬£¬ £¬Í¬Ê±»áÒÖÖÆVEGFR¡¢EGFRµÈÆäËûÂÑ°×£¬£¬£¬£¬£¬ £¬ÓÐÓÃÐÔÏà¶Ô½Ï²î£¬£¬£¬£¬£¬ £¬ÇÒ¸±×÷ÓúͷǰÐÏò¶¾ÐÔÔöÌí¡£ ¡£¡£¡£¡£ ¡£¡£¡£2020Äê5ÔÂ9ÈÕ£¬£¬£¬£¬£¬ £¬FDA¼ÓËÙÅú×¼ÁËLoxo Oncology¹«Ë¾(ÀñÀ´ÆìÏÂ)selpercatinib(LOXO-292£¬£¬£¬£¬£¬ £¬Retevmo)ÉÏÊУ¬£¬£¬£¬£¬ £¬ÓÃÓÚÖÎÁƲ¿·ÖRETÈںϻùÒòµÄ·ÇСϸ°û·Î°©³ÉÈË»¼Õߣ¬£¬£¬£¬£¬ £¬ºÍÍíÆÚRETÍ»±äÑôÐÔ¼××´ÏÙËèÑù°©(MTC)»¼Õß¼°ÍíÆÚ»òתÒƵÄRETÈÚºÏÑôÐÔ¼××´ÏÙ°©»¼Õß¡£ ¡£¡£¡£¡£ ¡£¡£¡£ÕâÊÇFDAÅú×¼µÄÊ׿î¸ßÑ¡ÔñÐÔRET¼¤Ã¸ÒÖÖƼÁ¡£ ¡£¡£¡£¡£ ¡£¡£¡£Selpercatinib(LOXO-292)ÊÇ¿Ú·þÓÃÒ©µÄATP¾ºÕùÐÔС·Ö×ÓRET¼¤Ã¸ÒÖÖƼÁ£¬£¬£¬£¬£¬ £¬Ëü¾ßÓд©Í¸ÖÐÊàÉñ¾ÏµÍ³(CNS)µÄÄÜÁ¦£¬£¬£¬£¬£¬ £¬²¢ÇÒ¿ÉÒÔ°ÐÏò¼¤»îÐÔRETÈںϡ¢µãÍ»±äºÍijЩ»ñµÃÐÔÄÍÒ©Í»±ä(¶Ô°üÀ¨KIF5B-RETºÍCCDC6-RETÈÚºÏÀàÐÍ£¬£¬£¬£¬£¬ £¬ÒÔ¼°RET-V804L/MºÍM918TÄÍÒ©Í»±äÃô¸Ð)[1]¡£ ¡£¡£¡£¡£ ¡£¡£¡£2020Äê9ÔÂ5ÈÕ£¬£¬£¬£¬£¬ £¬FDAÅú×¼À¶Í¼¹«Ë¾(Blueprint Medicines Corporation)¿ª·¢µÄRETÒÖÖƼÁPralsetinib(BLU-667£¬£¬£¬£¬£¬ £¬Gavreto)ÉÏÊУ¬£¬£¬£¬£¬ £¬ÓÃÓÚÖÎÁÆRETÈÚºÏÑôÐÔתÒÆÐÔ·ÇСϸ°û·Î°©(NSCLC)³ÉÈË»¼Õß[1]¡£ ¡£¡£¡£¡£ ¡£¡£¡£2021Äê3ÔÂ24ÈÕ£¬£¬£¬£¬£¬ £¬BLU667(ÆÕÀÌæÄá, ÉÌÆ·Ãû£ºÆÕ¼ª»ª®)»ñµÃÖйú¹ú¼ÒÒ©Æ·¼àÊÓÖÎÀí¾Ö(NMPA)Åú×¼£¬£¬£¬£¬£¬ £¬ÓÃÓÚ¼ÈÍù½ÓÊܹýº¬²¬»¯ÁƵÄRET»ùÒòÈÚºÏÑôÐԵľֲ¿ÍíÆÚ»òתÒÆÐÔNSCLC³ÉÈË»¼Õߣ¬£¬£¬£¬£¬ £¬³ÉΪº£ÄÚÊ׸öÒ²ÊÇÏÖÔÚΨһ»ñÅúµÄRETÒÖÖƼÁ[1]¡£ ¡£¡£¡£¡£ ¡£¡£¡£
²»¹ý£¬£¬£¬£¬£¬ £¬ÓÌÈçÆäËû°ÐÏòÒ©Ò»Ñù£¬£¬£¬£¬£¬ £¬ÄÍÒ©ÊDz»¿É×èÖ¹µÄ¡£ ¡£¡£¡£¡£ ¡£¡£¡£2020Äê1ÔÂ24ÈÕ£¬£¬£¬£¬£¬ £¬¡¶J Thorac Oncol¡·±¨µÀÁË2ÀýRETÈںϷÇСϸ°û·Î°©»¼ÕßÔÚʹÓÃLOXO-292ºó·ºÆðÈܼÁÇ°ÑØÍ»±ä(RET G810R/S/C)£¬£¬£¬£¬£¬ £¬½ø¶øµ¼ÖÂLOXO-292ÄÍÒ©¡£ ¡£¡£¡£¡£ ¡£¡£¡£½á¹¹Ä£×ÓÕ¹Íû£¬£¬£¬£¬£¬ £¬RETÈܼÁÇ°ÑØÍ»±äG810R/S/C/VÍ»±äÔÚ¿Õ¼äÉÏ×è°ÁËSelpercatinibµÄÁ¬Ïµ£¬£¬£¬£¬£¬ £¬ÌåÍâÊÔÑé֤ʵ¿¹RET¶à¼¤Ã¸ÒÖÖƼÁMKIºÍÑ¡ÔñÐÔRET TKIs¾ùʧȥ»îÐÔ£¬£¬£¬£¬£¬ £¬Pralsetinib(BLU-667)¶ÔG810SÃô¸Ð[6]¡£ ¡£¡£¡£¡£ ¡£¡£¡£2021Äê4ÔÂ10ºÅ£¬£¬£¬£¬£¬ £¬Loxo Oncology¹«Ë¾±¨µÀ£¬£¬£¬£¬£¬ £¬ÔÚ»¼ÕßÖзºÆðRETÈܼÁÇ°ÑØÍ»±äG810λµãºÍÃÅ¿ØÍ»±äV804λµãµÄË«Í»±ä£¬£¬£¬£¬£¬ £¬¼°M918TλµãºÍÈܼÁÇ°ÑØÍ»±äG810λµãµÄË«Í»±ä¡£ ¡£¡£¡£¡£ ¡£¡£¡£ÌåÍâʵÑéЧ¹ûÏÔʾ£¬£¬£¬£¬£¬ £¬RET±¬·¢Ë«Í»±äºó£¬£¬£¬£¬£¬ £¬¶ÔSelpercatinib(LOXO-292)ºÍPralsetinib(BLU-667)ÒÖÖƼÁ²»Ãô¸Ð[7]¡£ ¡£¡£¡£¡£ ¡£¡£¡£
ͼ4. Ñ¡ÔñÐÔRETÒÖÖƼÁÄÍÒ©ÐÔµÄÄ£Äâ¡£ ¡£¡£¡£¡£ ¡£¡£¡£
(ͼƬȪԴÓڲο¼×ÊÁÏ[6])
Õë¶ÔRET¼¤Ã¸ÒÖÖƼÁÒ©Î￪·¢ºÍÐèÇ󣬣¬£¬£¬£¬ £¬ÀûÀ´w66¹¹½¨Ò»ÏµÁÐBa/F3-RETË«Í»±äµÄ¹¤³Ìϸ°ûÖ꣬£¬£¬£¬£¬ £¬ÓÃÓÚÕë¶ÔRET°ÐµãµÄ»¯ºÏÎïɸÐò¼°¶¯ÎïҩЧÆÀ¼Û£¬£¬£¬£¬£¬ £¬½Ó´ý¿í´ó¿Í»§×ÉѯÏàÖú¡£ ¡£¡£¡£¡£ ¡£¡£¡£
ϸ°ûÖêÁбí
²¿·Öϸ°ûÖêÌåÍâÑéÖ¤Êý¾Ý
²¿·Öϸ°ûÖêÌåÄÚÄ£×ÓÑéÖ¤Êý¾Ý
BLU-667 in Ba/F3-KIF5B-RET Model
BLU-667¡¢LOXO-292 in Ba/F3-KIF5B-RET-V804M Model
BLU-667¡¢LOXO-292 in Ba/F3-KIF5B-RET-V804L Model
BLU-667¡¢LOXO-292 in Ba/F3-KIF5B-RET-G810C Model
BLU-667¡¢LOXO-292 in Ba/F3-KIF5B-RET-G810R Model
BLU-667¡¢LOXO-292 in Ba/F3-KIF5B-RET-G810S Model
²¿·ÖCDXÄ£×ÓÑéÖ¤Êý¾Ý
LOXO-292 in LC-2/ad Model
LOXO-292 in TT Model
²Î¿¼ÎÄÏ×¼°Í¼Æ¬ÈªÔ´£º
1. The importance of the RET gene in thyroid cancer and therapeutic implications. Nature, 2021 May,17:296–306.
2. To Bud or not to Bud: The RET perspective in CAKUT. Pediatr Nephrol. 2014 Apr; 29(4): 597–608.
3. RET Aberrations in Diverse Cancers. Clin Cancer Res; 23(8) April 15, 2017,1988-1997.
4. Curigliano G, et al. 2021 ASCO, Poster 9089.
5.Öйú·ÇСϸ°û·Î°© RET »ùÒòÈÚºÏÁÙ´²¼ì²âר¼Ò¹²Ê¶. Öлª²¡ÀíѧÔÓÖ¾, 2021, 50(6): 583-591.
6. RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies. Journal of Thoracic Oncology Vol. 2020.15 No. 4: 541-549.
7. Pre-clinical characterization of potent and selective next-generation RET inhibitors. Loxo Oncology at Lilly. Presented at: AACR Annual Meeting 2021.
ÀûÀ´w66¹«ÖÚºÅ
Á¢ÒìÒ©ÎïÆÀ¼Û
ÖпÆÒ½ÂöС³ÌÐò
µç»°£º4006 0551 06£¨¹Ù·½ÈÈÏߣ©
0551—67129201£¨¹«Ë¾×ܲ¿£©
꿅᣼www.precedo.cn
µØµã£ººÏ·ÊÊиßÐÂÇøÏ°ÓÑ·¹ú¼Ò¿µ½¡´óÊý¾Ý¹¤ÒµÔ°A6¶°
Copyright © 2021 ÀûÀ´w66 °æȨËùÓÐ | SEO±êÇ©
ÍøÕ¾½¨É裺ÖÐÆó¶¯Á¦ ºÏ·Ê